Veronika Maria Metzler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Veronika Maria Metzler has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- David M. Heery
University of Nottingham
3 shared publications - Nigel Patrick Mongan
School of Veterinary Medicine and Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham LE12 5RD, UK
3 shared publications - Catrin Sian Rutland
School of Veterinary Medicine and Sciences, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham LE12 5RD, UK
2 shared publications Christian Pritz
Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria
2 shared publicationsHerbert Riechelmann
Department of Otorhinolaryngology and Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria
2 shared publicationsJennie N. Jeyapalan
Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK
2 shared publications
Latest Publications
- Open Access
- 20 November 2017
- Published by SAGE Publications in Tumor Biology
- Vol. 39 (11)
Separation of cell survival, growth, migration, and mesenchymal transdifferentiation effects of fibroblast secretome on tumor cells of head and neck squamous cell carcinoma
Fibroblasts play a central role in tumor invasion, recurrence, and metastasis in head and neck squamous cell carcinoma. The aim of this study was to investigate the influence of tumor cell self-produced factors and paracrine fibroblast–secreted factors in comparison to indirect co-culture on cancer cell survival, growth, migration, and epithelial–mesenchymal transition using the cell lines SCC-25 and human gingival fibroblasts. Thereby, we particularly focused on the participation of the fibroblast-secreted transforming growth factor beta-1.Tumor cell self-produced factors were sufficient to ensure tumor cell survival and basic cell growth, but fibroblast-secreted paracrine factors significantly increased cell proliferation, migration, and epithelial–mesenchymal transition–related phenotype changes in tumor cells. Transforming growth factor beta-1 generated individually migrating disseminating tumor cell groups or single cells separated from the tumor cell nest, which were characterized by reduced E-cadherin expression. At the same time, transforming growth factor beta-1 inhibited tumor cell proliferation under serum-starved conditions. Neutralizing transforming growth factor beta antibody reduced the cell migration support of fibroblast-conditioned medium. Transforming growth factor beta-1 as a single factor was sufficient for generation of disseminating tumor cells from epithelial tumor cell nests, while other fibroblast paracrine factors supported tumor nest outgrowth. Different fibroblast-released factors might support tumor cell proliferation and invasion, as two separate effects.
- 20 November 2017
- Published by SAGE Publications in Tumor Biology
- Vol. 39 (11)
Open AccessSeparation of cell survival, growth, migration, and mesenchymal transdifferentiation effects of fibroblast secretome on tumor cells of head and neck squamous cell carcinoma
Fibroblasts play a central role in tumor invasion, recurrence, and metastasis in head and neck squamous cell carcinoma. The aim of this study was to investigate the influence of tumor cell self-produced factors and paracrine fibroblast–secreted factors in comparison to indirect co-culture on cancer cell survival, growth, migration, and epithelial–mesenchymal transition using the cell lines SCC-25 and human gingival fibroblasts. Thereby, we particularly focused on the participation of the fibroblast-secreted transforming growth factor beta-1.Tumor cell self-produced factors were sufficient to ensure tumor cell survival and basic cell growth, but fibroblast-secreted paracrine factors significantly increased cell proliferation, migration, and epithelial–mesenchymal transition–related phenotype changes in tumor cells. Transforming growth factor beta-1 generated individually migrating disseminating tumor cell groups or single cells separated from the tumor cell nest, which were characterized by reduced E-cadherin expression. At the same time, transforming growth factor beta-1 inhibited tumor cell proliferation under serum-starved conditions. Neutralizing transforming growth factor beta antibody reduced the cell migration support of fibroblast-conditioned medium. Transforming growth factor beta-1 as a single factor was sufficient for generation of disseminating tumor cells from epithelial tumor cell nests, while other fibroblast paracrine factors supported tumor nest outgrowth. Different fibroblast-released factors might support tumor cell proliferation and invasion, as two separate effects.
- Open Access
- 18 August 2017
- Published by Wiley in Clinical Endocrinology
- Vol. 87 (5) , 557-565
Expression ofNAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome
Summary: Objective: Women with a prior history of polycystic ovary syndrome (PCOS) have an increased risk of endometrial cancer (EC).Aim: To investigate whether the endometrium of women withPCOSpossesses gene expression changes similar to those found inEC.Design and Methods: Patients withEC,PCOSand control women unaffected by eitherPCOSorECwere recruited into a cross‐sectional study at the Nottingham University Hospital,UK. ForRNAsequencing, representative individual endometrial biopsies were obtained from women withEC,PCOSand a woman unaffected byPCOSorEC. Expression of a subset of differentially expressed genes identified byRNAsequencing, includingNAD(P)H quinone dehydrogenase 1 (NQO1), was validated by quantitative reverse transcriptasePCRvalidation (n = 76) and in the cancer genome atlasUCEC(uterine corpus endometrioid carcinoma)RNAsequencing data set (n = 381). The expression ofNQO1 was validated by immunohistochemistry inECsamples from a separate cohort (n = 91) comprised of consecutive patients who underwent hysterectomy at St Mary's Hospital, Manchester, between 2011 and 2013. A further 6 postmenopausal women with histologically normal endometrium who underwent hysterectomy for genital prolapse were also included. Informed consent and local ethics approval were obtained for the study.Results: We show for the first thatNQO1expression is significantly increased in the endometrium of women withPCOSandEC. Immunohistochemistry confirms significantly increasedNQO1 protein expression inECrelative to nonmalignant endometrial tissue (P < .0001).Conclusions: The results obtained here support a previously unrecognized molecular link betweenPCOSandECinvolvingNQO1.
- 18 August 2017
- Published by Wiley in Clinical Endocrinology
- Vol. 87 (5) , 557-565
Open AccessExpression ofNAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome
Summary: Objective: Women with a prior history of polycystic ovary syndrome (PCOS) have an increased risk of endometrial cancer (EC).Aim: To investigate whether the endometrium of women withPCOSpossesses gene expression changes similar to those found inEC.Design and Methods: Patients withEC,PCOSand control women unaffected by eitherPCOSorECwere recruited into a cross‐sectional study at the Nottingham University Hospital,UK. ForRNAsequencing, representative individual endometrial biopsies were obtained from women withEC,PCOSand a woman unaffected byPCOSorEC. Expression of a subset of differentially expressed genes identified byRNAsequencing, includingNAD(P)H quinone dehydrogenase 1 (NQO1), was validated by quantitative reverse transcriptasePCRvalidation (n = 76) and in the cancer genome atlasUCEC(uterine corpus endometrioid carcinoma)RNAsequencing data set (n = 381). The expression ofNQO1 was validated by immunohistochemistry inECsamples from a separate cohort (n = 91) comprised of consecutive patients who underwent hysterectomy at St Mary's Hospital, Manchester, between 2011 and 2013. A further 6 postmenopausal women with histologically normal endometrium who underwent hysterectomy for genital prolapse were also included. Informed consent and local ethics approval were obtained for the study.Results: We show for the first thatNQO1expression is significantly increased in the endometrium of women withPCOSandEC. Immunohistochemistry confirms significantly increasedNQO1 protein expression inECrelative to nonmalignant endometrial tissue (P < .0001).Conclusions: The results obtained here support a previously unrecognized molecular link betweenPCOSandECinvolvingNQO1.
- 21 September 2016
- Published by Bioscientifica in Endocrine Abstracts
Lysine demethylase 7A (KDM7A) as a potential therapeutic target in prostate cancer
Androgen Receptor (AR) is central to prostate cancer (PCa) tumorigenesis and metastases. The genomic actions of androgens are mediated by the AR in complex with multiple chromatin modifying coregulators. We and others have identified lysine demethylases (KDMs) as important mediators of androgen signaling and increased expression of specific coregulators, including KDM1A, are implicated in PCa recurrence. There is an urgent need for new PCa treatments. While androgen deprivation therapies (ADT) impede tumor progression, castrate resistant PCa (CRPC) typically arises within ~18 months. CRPCs escape androgen dependency and are incurable. The mechanisms involved in CRPC include AR mutations/splice variants and/or alterations in AR-coregulators. However AR-coregulators, in particular ‘druggable’ enzymes including KDMs, offer alternative targets to circumvent resistance to existing ADTs. We reported that the androgen-induced microRNA-137 (miR137) acts as a suppressor of an extended network of transcriptional coregulators, including KDM1A and KDM7A, in normal prostate cells. However loss of miR137 in PCa contributes to increased expression of these coregulators. Here we report that androgen induces KDM7A expression in hormone responsive LNCaP cells. siRNA-mediated functional depletion of KDM7A expression impairs androgen induction of KLK3/PSA and the pro-angiogenesis factor VEGFA in LNCaP and its hormone-refractory derivative, LNCaP:C4-2. We examined KDM7A expression in PCa specimens and correlate expression with key clinical parameters. Collectively our data supports a role for KDM7A in androgen dependent and refractory PCa. Thus KDM7A, like KDM1A, represents a novel potential drug-target to inhibit androgen signaling in hormone dependent and refractory contexts and thereby potentially circumvent resistance to existing ADTs. Funding: We gratefully acknowledge the financial support of the BBSRC doctoral training program and the University of Nottingham. Presenting author: Veronika Metzler, Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Health Sciences, University of Nottingham, UK. Email: stxvm8@nottingham.ac.uk.
- 21 September 2016
- Published by Bioscientifica in Endocrine Abstracts
Lysine demethylase 7A (KDM7A) as a potential therapeutic target in prostate cancer
Androgen Receptor (AR) is central to prostate cancer (PCa) tumorigenesis and metastases. The genomic actions of androgens are mediated by the AR in complex with multiple chromatin modifying coregulators. We and others have identified lysine demethylases (KDMs) as important mediators of androgen signaling and increased expression of specific coregulators, including KDM1A, are implicated in PCa recurrence. There is an urgent need for new PCa treatments. While androgen deprivation therapies (ADT) impede tumor progression, castrate resistant PCa (CRPC) typically arises within ~18 months. CRPCs escape androgen dependency and are incurable. The mechanisms involved in CRPC include AR mutations/splice variants and/or alterations in AR-coregulators. However AR-coregulators, in particular ‘druggable’ enzymes including KDMs, offer alternative targets to circumvent resistance to existing ADTs. We reported that the androgen-induced microRNA-137 (miR137) acts as a suppressor of an extended network of transcriptional coregulators, including KDM1A and KDM7A, in normal prostate cells. However loss of miR137 in PCa contributes to increased expression of these coregulators. Here we report that androgen induces KDM7A expression in hormone responsive LNCaP cells. siRNA-mediated functional depletion of KDM7A expression impairs androgen induction of KLK3/PSA and the pro-angiogenesis factor VEGFA in LNCaP and its hormone-refractory derivative, LNCaP:C4-2. We examined KDM7A expression in PCa specimens and correlate expression with key clinical parameters. Collectively our data supports a role for KDM7A in androgen dependent and refractory PCa. Thus KDM7A, like KDM1A, represents a novel potential drug-target to inhibit androgen signaling in hormone dependent and refractory contexts and thereby potentially circumvent resistance to existing ADTs. Funding: We gratefully acknowledge the financial support of the BBSRC doctoral training program and the University of Nottingham. Presenting author: Veronika Metzler, Faculty of Medicine and Health Sciences, School of Veterinary Medicine and Health Sciences, University of Nottingham, UK. Email: stxvm8@nottingham.ac.uk.
- Open Access
- 20 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (3) , 2508-2518
Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells
Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells
- 20 October 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (3) , 2508-2518
Open AccessTumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells
Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells